NY-AQARA
28.7.2021 10:02:05 CEST | Business Wire | Press release
Aqara, a provider for smart home products, announced the launch of its first Amazon store in Europe, the Aqara Amazon UK store . Starting from July 28, 2021, a comprehensive suite of Aqara products will be made available on Amazon UK to residents not only in the UK, but also in dozens of European countries that are covered in the Amazon network.
Aqara has been selling smart home products in Europe since 2020 via dozens of authorized distributors , and has become one of the most popular brands among the European smart home community for the high product quality, the accessible prices and the seamless integration with major ecosystems including Apple HomeKit, Amazon Alexa, Google Assistant, and more.
The launch of Aqara’s first Amazon Europe store marks another milestone for the fast-growing brand, offering millions of European consumers an easy and convenient access to the Aqara product lineup. Following its UK Amazon store, Aqara is expected to add two more brand stores on Amazon France and Amazon Germany in the following months.
The product lineup on the Aqara Amazon UK store include:
Aqara Hub M2 (£54.99*) - Aqara’s most advanced and future-proof smart home hub that connects all Aqara devices and allows seamless integration across Aqara sensors and home automation devices;
Aqara Camera Hub G2H (£64.99) - An indoor HomeKit Secure Video camera for home security, with the Zigbee hub function to enhance home security and smart home automations;
Aqara Door & Window Sensor (£17.99) - It detects if a window or a door is open in real time, and enables push notifications or/and local alarm activation when the door/ window opens unexpectedly;
Aqara Temperature & Humidity Sensor (£19.99) - It monitors temperature, humidity, and atmospheric pressure in real time, and can connect with other Aqara devices for home automations and scenes;
Aqara Motion Sensor (£21.99) - It detects human movements with passive infrared and can work with other Aqara products to set home automations and scenes, such as turning on/off lights when it detects activity or inactivity;
Aqara Water Leak Sensor (£19.99) - It detects flood, and enables push notifications or/and local alarm activation to protect the property;
Aqara Vibration Sensor (£19.99) - It detects vibration, tilt and drop, alerts users when unexpected movement is detected, and can be used for home automations and scenes;
Aqara Wireless Switch H1 (£26.99) - A remote switch with 7 configurable actions to control smart home devices or home scenes;
Aqara Wireless Mini Switch (£17.99) - A versatile and compact switch with 3 configurable actions to control smart home devices or home scenes;
Aqara Cube (£19.99) - A versatile controlling cube that recognizes 6 gestures (push, shake, rotate, tap twice, flip 90°, and flip 180°) for smart home control;
Aqara TVOC Air Quality Monitor** (£39.99) - It detects the concentration and level of total volatile organic compounds (TVOC) in the air, as well as temperature and humidity, and can be bound with an Aqara hub to enable home automations;
Aqara Smart Wall Switch H1 EU** (£39.99-£42.99) - Aqara’s first wall switch designed for Europe, available in both With Neutral and No Neutral versions;
To celebrate the launch, Aqara now offers a limited-time discount of 10% OFF for all purchases on its Amazon UK store with the promo code: AmazonUKPR. The offering is valid through July 30, 2021.
* All prices include VAT.
** Aqara TVOC Air Quality Monitor and Wall Switch H1 EU will be available on Amazon UK in the following weeks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005229/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom